First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony

Descripción del Articulo

Se evaluó si el antimonio pentavalente (un fármaco antiparasitario) combinado con imiquimod (un inmunomodulador) sería más eficaz que el antimonio pentavalente solo en pacientes con leishmaniasis cutánea que no habían sido tratados previamente. Se realizó un estudio clínico doble ciego randomizado c...

Descripción completa

Detalles Bibliográficos
Autores: Miranda-Verastegui, Cesar, Tulliano, GianFranco, Gyorkos, Theresa W., Calderon, Wessmark, Rahme, Elham, Ward, Brian, Cruz, Maria, Llanos Cuentas, Alejandro, Matlashewski, Greg
Formato: artículo
Fecha de Publicación:2009
Institución:Seguro Social de Salud
Repositorio:ESSALUD-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorio.essalud.gob.pe:20.500.12959/403
Enlace del recurso:https://hdl.handle.net/20.500.12959/403
https://doi.org/10.1371/journal.pntd.0000491
Nivel de acceso:acceso abierto
Materia:Enfermedades Infecciosas
Leishmaniasis Cutánea
Acciones Farmacológicas
Factores Inmunológicos
https://purl.org/pe-repo/ocde/ford#3.05.00
id ESSA_8b4526cbe18d7d3860f27d9d0bb3528d
oai_identifier_str oai:repositorio.essalud.gob.pe:20.500.12959/403
network_acronym_str ESSA
network_name_str ESSALUD-Institucional
repository_id_str 4277
dc.title.es_PE.fl_str_mv First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony
title First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony
spellingShingle First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony
Miranda-Verastegui, Cesar
Enfermedades Infecciosas
Leishmaniasis Cutánea
Acciones Farmacológicas
Factores Inmunológicos
https://purl.org/pe-repo/ocde/ford#3.05.00
title_short First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony
title_full First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony
title_fullStr First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony
title_full_unstemmed First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony
title_sort First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony
author Miranda-Verastegui, Cesar
author_facet Miranda-Verastegui, Cesar
Tulliano, GianFranco
Gyorkos, Theresa W.
Calderon, Wessmark
Rahme, Elham
Ward, Brian
Cruz, Maria
Llanos Cuentas, Alejandro
Matlashewski, Greg
author_role author
author2 Tulliano, GianFranco
Gyorkos, Theresa W.
Calderon, Wessmark
Rahme, Elham
Ward, Brian
Cruz, Maria
Llanos Cuentas, Alejandro
Matlashewski, Greg
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Miranda-Verastegui, Cesar
Tulliano, GianFranco
Gyorkos, Theresa W.
Calderon, Wessmark
Rahme, Elham
Ward, Brian
Cruz, Maria
Llanos Cuentas, Alejandro
Matlashewski, Greg
dc.subject.es_PE.fl_str_mv Enfermedades Infecciosas
Leishmaniasis Cutánea
Acciones Farmacológicas
Factores Inmunológicos
topic Enfermedades Infecciosas
Leishmaniasis Cutánea
Acciones Farmacológicas
Factores Inmunológicos
https://purl.org/pe-repo/ocde/ford#3.05.00
dc.subject.ocde.es_PE.fl_str_mv https://purl.org/pe-repo/ocde/ford#3.05.00
description Se evaluó si el antimonio pentavalente (un fármaco antiparasitario) combinado con imiquimod (un inmunomodulador) sería más eficaz que el antimonio pentavalente solo en pacientes con leishmaniasis cutánea que no habían sido tratados previamente. Se realizó un estudio clínico doble ciego randomizado con 80 pacientes con leishmaniasis cutánea. Los pacientes de estudio fueron seleccionados en Lima y Cusco, 20 experimentales y 20 sujetos de control en cada lugar. Se concluye que el tratamiento combinado de imiquimod con antimonio pentavalente fue más efectivo que el placebo con antimonio pentavalente, pero la diferencia no fue significativa estadísticamente.
publishDate 2009
dc.date.accessioned.none.fl_str_mv 2019-04-24T13:44:03Z
dc.date.available.none.fl_str_mv 2019-04-24T13:44:03Z
dc.date.issued.fl_str_mv 2009
dc.type.es_PE.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.citation.es_PE.fl_str_mv PLOS Neglected Tropical Diseases. 2009;3(7).
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12959/403
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1371/journal.pntd.0000491
identifier_str_mv PLOS Neglected Tropical Diseases. 2009;3(7).
url https://hdl.handle.net/20.500.12959/403
https://doi.org/10.1371/journal.pntd.0000491
dc.language.iso.es_PE.fl_str_mv eng
language eng
dc.relation.uri.none.fl_str_mv https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0000491#abstract1
dc.rights.es_PE.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.es_PE.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.format.es_PE.fl_str_mv application/pdf
dc.publisher.es_PE.fl_str_mv Marleen Boelaert, Institute of Tropical Medicine, Belgium
dc.publisher.country.es_PE.fl_str_mv PE
dc.source.es_PE.fl_str_mv Seguro Social de Salud (EsSalud)
Repositorio Institucional EsSalud
dc.source.none.fl_str_mv reponame:ESSALUD-Institucional
instname:Seguro Social de Salud
instacron:ESSALUD
instname_str Seguro Social de Salud
instacron_str ESSALUD
institution ESSALUD
reponame_str ESSALUD-Institucional
collection ESSALUD-Institucional
bitstream.url.fl_str_mv https://repositorio.essalud.gob.pe/bitstream/20.500.12959/403/1/First-line%20therapy%20for%20human%20cutaneous%20leishmaniasis%20in%20Peru%20using%20the%20TLR7%20agonist%20imiquimod%20in.pdf
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/403/2/license.txt
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/403/3/First-line%20therapy%20for%20human%20cutaneous%20leishmaniasis%20in%20Peru%20using%20the%20TLR7%20agonist%20imiquimod%20in.pdf.txt
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/403/4/First-line%20therapy%20for%20human%20cutaneous%20leishmaniasis%20in%20Peru%20using%20the%20TLR7%20agonist%20imiquimod%20in.pdf.jpg
bitstream.checksum.fl_str_mv 63e913f86519ac9da92f7c20d79b74be
8a4605be74aa9ea9d79846c1fba20a33
db42243e1e633bf5c0c5cced924541ce
edf20e731ac0c77aa0cf2a7e512aef37
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Seguro Social de Salud – ESSALUD
repository.mail.fl_str_mv bibliotecacentral@essalud.gob.pe
_version_ 1813537133920518144
spelling Miranda-Verastegui, CesarTulliano, GianFrancoGyorkos, Theresa W.Calderon, WessmarkRahme, ElhamWard, BrianCruz, MariaLlanos Cuentas, AlejandroMatlashewski, Greg2019-04-24T13:44:03Z2019-04-24T13:44:03Z2009PLOS Neglected Tropical Diseases. 2009;3(7).https://hdl.handle.net/20.500.12959/403https://doi.org/10.1371/journal.pntd.0000491Se evaluó si el antimonio pentavalente (un fármaco antiparasitario) combinado con imiquimod (un inmunomodulador) sería más eficaz que el antimonio pentavalente solo en pacientes con leishmaniasis cutánea que no habían sido tratados previamente. Se realizó un estudio clínico doble ciego randomizado con 80 pacientes con leishmaniasis cutánea. Los pacientes de estudio fueron seleccionados en Lima y Cusco, 20 experimentales y 20 sujetos de control en cada lugar. Se concluye que el tratamiento combinado de imiquimod con antimonio pentavalente fue más efectivo que el placebo con antimonio pentavalente, pero la diferencia no fue significativa estadísticamente.Background: Current therapies for cutaneous leishmaniasis are limited by poor efficacy, long-term course of treatment, and the development of resistance. We evaluated if pentavalent antimony (an anti-parasitic drug) combined with imiquimod (an immunomodulator) was more effective than pentavalent antimony alone in patients who had not previously been treated. Methods: A randomized double-blind clinical trial involving 80 cutaneous leishmaniasis patients was conducted in Peru. The study subjects were recruited in Lima and Cusco (20 experimental and 20 control subjects at each site). Experimental arm: Standard dose of pentavalent antimony plus 5% imiquimod cream applied to each lesion three times per week for 20 days. Control arm: Standard dose of pentavalent antimony plus placebo (vehicle cream) applied as above. The primary outcome was cure defined as complete re-epithelization with no inflammation assessed during the 12 months post-treatment period. Results: Of the 80 subjects enrolled, 75 completed the study. The overall cure rate at the 12-month follow-up for the intention-to-treat analysis was 75% (30/40) in the experimental arm and 58% (23/40) in the control arm (p = 0.098). Subgroup analyses suggested that combination treatment benefits were most often observed at the Cusco site, where L. braziliensis is the prevalent species. Over the study period, only one adverse event (rash) was recorded, in the experimental arm. Conclusion: The combination treatment of imiquimod plus pentavalent antimony performed better than placebo plus pentavalent antimony, but the difference was not statistically significant.application/pdfengMarleen Boelaert, Institute of Tropical Medicine, BelgiumPEhttps://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0000491#abstract1info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/4.0/Seguro Social de Salud (EsSalud)Repositorio Institucional EsSaludreponame:ESSALUD-Institucionalinstname:Seguro Social de Saludinstacron:ESSALUDEnfermedades InfecciosasLeishmaniasis CutáneaAcciones FarmacológicasFactores Inmunológicoshttps://purl.org/pe-repo/ocde/ford#3.05.00First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimonyinfo:eu-repo/semantics/articleORIGINALFirst-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in.pdfFirst-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in.pdfapplication/pdf354171https://repositorio.essalud.gob.pe/bitstream/20.500.12959/403/1/First-line%20therapy%20for%20human%20cutaneous%20leishmaniasis%20in%20Peru%20using%20the%20TLR7%20agonist%20imiquimod%20in.pdf63e913f86519ac9da92f7c20d79b74beMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.essalud.gob.pe/bitstream/20.500.12959/403/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52TEXTFirst-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in.pdf.txtFirst-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in.pdf.txtExtracted texttext/plain46464https://repositorio.essalud.gob.pe/bitstream/20.500.12959/403/3/First-line%20therapy%20for%20human%20cutaneous%20leishmaniasis%20in%20Peru%20using%20the%20TLR7%20agonist%20imiquimod%20in.pdf.txtdb42243e1e633bf5c0c5cced924541ceMD53THUMBNAILFirst-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in.pdf.jpgFirst-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in.pdf.jpgGenerated Thumbnailimage/jpeg7580https://repositorio.essalud.gob.pe/bitstream/20.500.12959/403/4/First-line%20therapy%20for%20human%20cutaneous%20leishmaniasis%20in%20Peru%20using%20the%20TLR7%20agonist%20imiquimod%20in.pdf.jpgedf20e731ac0c77aa0cf2a7e512aef37MD5420.500.12959/403oai:repositorio.essalud.gob.pe:20.500.12959/4032023-08-02 11:29:33.831Repositorio Seguro Social de Salud – ESSALUDbibliotecacentral@essalud.gob.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
score 13.95948
First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares